Clinical Trial Update: Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating autologous bone marrow-derived stem cell transplantation for retinitis pigmentosa.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Snippet

Sponsor: Stem Cells Arabia | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: UNKNOWN